GlaxoSmithKline (GSK), a major player in vaccine manufacturing, is set to inaugurate a €100m vaccine production plant on Friday in a Hungarian city 30Km northeast of Budapest.
According to a GSK spokesman, the new site in Godollo will be one of Europe's most advanced biotechnology plants and will manufacture two types of vaccines, though more details were not disclosed.
The company employs around 360 people in Hungary and had turnover of €106.8m in 2005.
GSK earlier said it plans to manufacture DPT, a combination of three vaccines to immunise against diphtheria, pertussis and tetanus, at the Godollo plant.
The drugmaker plans output in the order of 100m units a year to cover its entire world-wide needs.
GSK was responsible for about a quarter of the $11bn (€8.6bn) of vaccine sales across the world last year, and expects to launch five major new vaccines over the next five years, including an improved flu vaccine for the elderly and a new meningitis treatment for infants.